Skip to main content
Pharma Equity Group A/S logo

Pharma Equity Group A/S — Investor Relations & Filings

Ticker · BLVIS ISIN · DK0061155009 LEI · 2138008SUI4D917FKN20 CO Financial and insurance activities
Open in API
Filings indexed 1,627 across all filing types
Latest filing 2018-03-31 Annual Report
Country DK Denmark
Listing CO BLVIS

About Pharma Equity Group A/S

https://bcbsfepvision.com/

Pharma Equity Group A/S is an investment company specializing in early-stage biotechnology, life science, and MedTech companies. The group's mission is to support its portfolio companies in developing novel therapies and effective medicines for unmet medical needs. A primary investment is its subsidiary, Reponex Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing treatments for serious, acute, and chronic inflammatory diseases. The company is actively expanding its portfolio through strategic acquisitions to support its growth.

Recent filings

Filing Released Lang Actions
Annual Report 2017
Annual Report Classification · 95% confidence The document is titled 'Årsrapport 2017' (Annual Report 2017) and provides a summary of the company's financial performance, including key figures like net results, equity, and book value per share for the fiscal year 2017. While it functions as a summary of the annual report, it contains substantive financial data and management's analysis of the business trends and outlook, fitting the criteria for an Annual Report (10-K) in the context of international filings where '10-K' serves as the standard code for comprehensive annual financial reporting. FY 2017
2018-03-31 Danish
Året 2017 i hovedtræk
Annual Report Classification · 100% confidence The document is titled 'Årsrapport 2017' (Annual Report 2017) for Blue Vision A/S. It contains comprehensive financial statements, management reports, independent auditor's reports, and notes to the accounts for the fiscal year ending December 31, 2017. It is clearly the full annual report, not an announcement or a summary. FY 2017
2018-03-31 English
Major Shareholding Notification 2018
Major Shareholding Notification Classification · 98% confidence The document is very short (447 characters) and explicitly states that Blue Vision A/S has received an attached notification ("vedlagte meddelelse"). The content details a shareholder, Johannes Møller Westh, stating that after a share sale, he no longer holds more than 5% of the issued share capital. This is a notification regarding a change in significant share ownership crossing a threshold (5%). This directly matches the definition for Major Shareholding Notification (MRQ). Although it is a short announcement, the content is specific enough to classify it as MRQ rather than the general fallback RNS, as it is not merely announcing the publication of a report but reporting a specific transaction/holding change.
2018-01-29 English
Director's Dealing 2018
Director's Dealing Classification · 95% confidence The document is very short (436 characters) and appears to be a notification regarding a change in shareholding status following a sale ('Efter aktiesalg disponerer jeg ikke længere over 5% af den udstedte aktiekapital'). This directly relates to changes in significant share ownership thresholds. The most appropriate category is Major Shareholding Notification (MRQ). Although it is a short notification, the content is specific enough to classify it as MRQ rather than the general fallback RNS, as it reports a specific event related to ownership percentage crossing a threshold.
2018-01-29 Danish
M&A Activity 2018
M&A Activity Classification · 99% confidence The document is a 'Selskabsmeddelelse' (Company Announcement) dated December 29, 2017, titled 'Blue Vision A/S indgår hensigtserklæring om salg af hoteldelen af Portinho S.A.' (Blue Vision A/S enters into Letter of Intent regarding the sale of the hotel part of Portinho S.A.). This announcement details the signing of a Letter of Intent (Hensigtserklæring) for the sale of a major asset segment. This type of announcement, concerning significant corporate transactions like asset sales or major negotiations, typically falls under Capital/Financing Update (CAP) or Regulatory Filings (RNS). Since it specifically discusses the framework for a potential transaction and its financial implications (value per share), it is most closely aligned with financing or capital structure activities, although it is not a formal financing round. Given the options, 'CAP' (Capital/Financing Update) is the best fit as it relates to a major transaction impacting the company's structure and value realization. It is not an Earnings Release (ER), Interim Report (IR), or a formal M&A bid (TAR), but rather an announcement about a strategic transaction framework.
2018-01-08 Danish
Major Shareholding Notification 2017
Major Shareholding Notification Classification · 95% confidence The document is very short (556 characters) and explicitly states that a notification ('vedlagte meddelelse') has been received regarding a major shareholder ('Storaktionærmeddelelse'). The content confirms that Jean Marcel Dühring now owns 5.1% of the share capital and voting rights. This directly relates to changes in significant share ownership, which corresponds to the Major Shareholding Notification (MRQ) definition. Although it is a notification *received* by the company, the core subject matter is a major shareholding change, making MRQ the most specific fit over the general RNS fallback. Given the brevity and the nature of announcing a change in ownership percentage, MRQ is appropriate.
2017-11-21 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.